SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:e3559261-6d75-4b45-9a5d-4fdfa8c1eb19"
 

Search: onr:"swepub:oai:lup.lub.lu.se:e3559261-6d75-4b45-9a5d-4fdfa8c1eb19" > The European Leukem...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Cornelissen, Jan J. (author)

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

  • Article/chapterEnglish2012

Publisher, publication year, extent ...

  • 2012-09-04
  • Springer Science and Business Media LLC,2012
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:e3559261-6d75-4b45-9a5d-4fdfa8c1eb19
  • https://lup.lub.lu.se/record/3184309URI
  • https://doi.org/10.1038/nrclinonc.2012.150DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:for swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Gratwohl, Alois (author)
  • Schlenk, Richard F. (author)
  • Sierra, Jorge (author)
  • Bornhaeuser, Martin (author)
  • Juliusson, GunnarLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)stem-gju (author)
  • Racil, Zdenek (author)
  • Rowe, Jacob M. (author)
  • Russell, Nigel (author)
  • Mohty, Mohamad (author)
  • Lowenberg, Bob (author)
  • Socie, Gerard (author)
  • Niederwieser, Dietger (author)
  • Ossenkoppele, Gert J. (author)
  • Stamcellscentrum (SCC)Avdelningen för stamcellsforskning (creator_code:org_t)

Related titles

  • In:Nature Reviews Clinical Oncology: Springer Science and Business Media LLC9:10, s. 579-5901759-47821759-4774

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view